An open, experienced, and passionate team

Robert Ang, MBBS, MBA, is President and CEO at Vor Bio since 2019. Prior to Vor Bio, Robert gained operational experience focused on strategy and business development through roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also has biotech venture capital experience at Frazier Healthcare Ventures, where he invested in companies such as Incline Therapeutics (now Novartis) and Alnara Pharmaceuticals (now Eli Lilly), and strategy consulting experience at the Boston Consulting Group. He also has general surgery training and his clinical practice centered around soft tissue surgery with an emphasis on solid organ transplants. He received his medical degree at the University of Western Australia and has an MBA with Honors from Columbia Business School. Robert also serves as an independent director at the early-stage cancer immunotherapy company Enara Bio, a member of the Board of Directors and Vice-Chair of the Alliance for Regenerative Medicine, and a member of the Healthcare and Pharmaceutical Management Advisory Board of Columbia Business School.

Learn more about Robert’s views on the industry, the workplace, and other business topics in his CEO Perspectives blog.

Tirtha Chakraborty, PhD brings extensive expertise in nucleic acid therapy as well as cell and gene therapy to his role as Chief Scientific Officer and Head of Technical Operations. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology. Prior to Sana, he served as the Head of Hematology at CRISPR Therapeutics, leading research on hemoglobin disorders. His team’s work on autologous cell therapy using gene edited hematopoietic stem cells paved the way to the first approved CRISPR engineered product, Casgevy, a treatment for Sickle Cell Disease. Before that, Tirtha built the mRNA platform at Moderna Therapeutics. In his academic life, he was trained as a molecular geneticist and focused on the role of small RNAs in lymphocyte development and lymphomagenesis in the laboratory of Professor Klaus Rajewsky at Harvard Medical School. Tirtha’s PhD thesis was on deciphering the molecular mechanism of naturally acquired immunity against the malarial parasite Plasmodium falciparum. Tirtha serves as a Scientific Advisory Board Member of Specific Biologics, a genome editing company, and as a Board Member and Scientific Advisory Board Member of the Belgium based DROIA Venture company, Vedra Therapeutics, focused on mitochondrial genome editing and delivery. In addition to his CSO responsibilities, he also oversees Technical Operations at Vor Bio.

Han Choi, MD, LLM brings to Vor Bio over 20 years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. Prior to joining Vor Bio, Han served as a Principal at Oracle Investment Management, Inc. until September 2024, where he managed its healthcare public and private equity portfolios. For over two decades at Oracle, Han was responsible for sourcing, negotiating, and managing investments in the pharmaceutical and biotechnology sectors and provided strategic advice to portfolio companies on clinical, business development, and capital market strategies. Prior to joining Oracle, he held positions of increasing responsibility in licensing and business development at Pharmacia Corporation and Bristol-Myers Squibb Company. Han received his M.D. from The Mount Sinai School of Medicine and holds law degrees from Harvard Law School, and Oxford University. He is also a licensed physician in New York State and a member of the New York State Bar, Third Judicial Department.

Tania Philipp, Chief People Officer, brings more than 20 years of experience helping early-stage life sciences companies grow and progress. As a member of the senior leadership team, she is responsible for building a skilled and experienced team that will help Vor Bio achieve its objectives. Tania has a passion for creating a collaborative company culture and for fostering team dynamics that support individual and organizational growth. Prior to joining Vor Bio, she was Vice President and Head of Human Resources at Tango Therapeutics, where she was responsible for developing and implementing the strategic human resources vision that supported the company’s objectives and defined its culture. Before Tango, Tania held various senior human resources positions for a number of companies, including Bavarian Nordic, Mendel Biotechnology, Sunesis Pharmaceuticals, Pearl Therapeutics (acquired by AstraZeneca), and Protein Design Labs. Tania holds a master’s degree in behavioral psychology from The University of the Pacific.

David Phillips has more than 28 years of extensive expertise in establishing the foundations of quality departments in multiple pharmaceutical and biotech companies. Prior to joining Vor Bio, David served as Vice President, Head of Quality at Beam Therapeutics where he built the quality management system from the ground up, spanning all GxP areas. He also served as Vice President, Head of Quality at Kiniksa Pharmaceuticals where he established the company’s overall strategic long-term vision for quality. Before Kiniksa, David was Vice President, Quality at Shire Pharmaceuticals prior to its acquisition by Takeda. Notably, David was a core member of the team responsible for the integration of a number of programs and companies acquired by Shire and was responsible for various aspects of quality product lifecycle planning, quality aspects of geographic expansion, and technical oversight of key quality functions across a network of more than 25 locations.

David’s experience working outside of the United States – at Lonza Biologics in Singapore and at VaxGen, Inc./Celltrion in South Korea– provides him with a valuable global perspective. While at Lonza, he helped establish the country’s first biologics manufacturing park. David holds an MBA in new product development and project management and a Bachelor of Science in biochemistry and polymer chemistry from the North Carolina State University.